Patient Engagement with US Food and Drug Administration and Dexcom Developers Leads to Product Safety Controls
Source
National Health Council
Link
Patient-Focused Medical Product Development Case Examples
Description of Case Study
The US Food and Drug Administration (FDA) engaged patients, parents/caregivers, and patient groups, along with manufacturers of the Dexcom G5 Continuous Glucose Monitoring System and Animas Vibe System, to understand safety concerns for young children using insulin pumps, particularly how they might use or misuse the device. This input directly informed device design by identifying risks (e.g., accidental boluses), leading to patient-informed safety features like a lockout mechanism. The purpose of engagement was to mitigate real-world use risks and ensure the device was safe and acceptable for pediatric patients and their families.
Quick Facts Organization name: Dexcom |
Product Type(s)
medical devices:
- implantable device
- therapeutic device
Product Medical Specialty Area(s)
- other: endocrinology
Stakeholders
- medtech company: internal clinical affairs/research and development teams
- medtech company: internal regulatory affairs teams
- medtech company: internal medical affairs teams
- patients and caregivers, patient organizations
- regulators
Methods and Sources of Patient Input
- patient advocacy organizations
Impact of Patient Engagement
- Identification of pediatric-specific use-related risks: Engagement with patients, parents, and caregivers surfaced real-world risk scenarios, specifically the risk of accidental insulin boluses caused by young children inadvertently operating the pump, that informed targeted design changes to address these hazards.
- Incorporation of patient-informed safety features: Patient and caregiver input directly led to the incorporation of a lockout mechanism designed to prevent unintended insulin delivery, reducing the risk of accidental bolus administration by young children.
- Increased caregiver confidence: By addressing the specific safety concerns raised by families, the resulting device design was more appropriate for pediatric use and better supported caregiver confidence in the ability of children to manage their condition safely.
Lessons Learned
The case illustrates that clinical and engineering evaluation alone may not surface use-related risks specific to pediatric patients and caregivers and that direct engagement with those populations can be helpful to identify real-world hazard scenarios early enough to inform device design. It also demonstrates the value of the FDA engaging patients and manufacturers together to address safety concerns collaboratively rather than sequentially.